After an often contentious annual shareholders' meeting last week, much of it due to Nokia's (NYSE: NOK ) decision to hitch its wagon to Microsoft's (NASDAQ: MSFT ) new Windows phone OS, the last thing shareholders needed was bad news. Unfortunately, that's just what they got when Gartner�issued its final Q1 2013 global phone sales results. A decline in overall mobile phone market share isn't surprising as Nokia makes the transition to Windows from its Symbian OS. What is surprising, and slightly depressing, is the direction Nokia is heading in worldwide smartphone market share.
The envelope, please
Samsung remains the leader in both feature and smartphone sales across the globe, growing 13% in total, and up 3.2 percentage points over the year-ago quarter. In the race for smartphone dominance with Apple (NASDAQ: AAPL ) , Samsung is winning the worldwide smartphone contest, and the lead is growing. Apple's share of the smartphone pie dropped to 18.2% in Q1, from 22.5% in the same period last year. And with no new phones expected for at least a quarter or two, and difficulties in securing subsidy deals with Asian wireless providers, things could get worse before they get better for Apple.
Digital River, Inc. provides end-to-end global cloud-commerce and marketing solutions. The company offers a range of services that enables its customers to establish an online sales channel. Its services include design, development, and hosting of online stores and shopping carts; store merchandising and optimization; order management; denied parties screening; export controls and management; tax compliance and management; fraud management; digital product delivery via download; physical product fulfillment; subscription management; online marketing, including email marketing; management of affiliate programs; paid search programs; payment processing services; Web site optimization, Web analytics, and reporting; and CD production and delivery services. The company also provides paid search advertising, search engine optimization, affiliate marketing, store optimization, multi-variant testing, and Web analytic and e-mail optimization services. In addition, it offers a range of payment processing services, such as multiple payment methods, fraud management, tax management, cloud-based billing, and other payment optimization services. The company sells its products and services through Internet and direct sales force. It serves software, consumer electronics, and computer and video game product manufacturers, as well as online channel partners, including retailers and affiliates in the United States, Austria, Brazil, China, Germany, Korea, Ireland, Japan, Luxembourg, Mexico, Singapore, Sweden, Taiwan, and the United Kingdom. Digital River, Inc. was founded in 1994 and is headquartered in Minnetonka, Minnesota.
Advisors' Opinion: - [By Alex Planes]
What: Shares of Digital River� (NASDAQ: DRIV ) are trading 8% higher in the afternoon after rocketing to an opening-bell gain of over 11% on Wednesday morning. Investors have cheered Digital River's strong first-quarter earnings and are reacting favorably to respectable (though not strong) guidance issued for the remainder of the fiscal year.
- [By Garrett Cook]
Digital River (NASDAQ: DRIV) shares shot up 47.58 percent to $25.65 after the company agreed to be acquired by an investor group led by Siris Capital Group for $26.00 per share in cash.
Top 10 Gas Utility Companies To Own For 2015: iShares MSCI Spain Capped ETF (ISVS)
iShares MSCI Spain Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Spanish market, as measured by the MSCI Spain Index (the Index). The Index seeks to measure the performance of the Spanish equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion: - [By abirk]
This San Jose, Calif.-based company offers a line of software and services used by professionals, marketers, knowledge workers, application developers, enterprises and consumers for creating, managing, delivering, measuring and engaging with content and experiences across multiple operating systems, devices and media. Adobe has three business segments: Digital Media, Digital Marketing, and Print and Publishing. The company distributes its products through a network of distributors, value-added resellers (VARs), systems integrators, independent software vendors (ISVs), retailers, and original equipment manufacturers (OEMs).
Top 10 Gas Utility Companies To Own For 2015: The Advisory Board Company(ABCO)
The Advisory Board Company, together with its subsidiaries, engages in the provision of best practices research and analysis, business intelligence and software tools, and management and advisory services primarily in the United States. The company offers various programs and services, including best practices research services that focus on identifying best-demonstrated management practices, critiquing widely-followed but ineffective practices, and analyzing emerging trends in the health care and education industries; business intelligence and software tools, which allow members to pair their own operational data with the best practices insights; and management and advisory services programs for assisting member institutions to adopt and implement best practices to enhance performance. As of June 30, 2011, it provided 51 distinct membership programs to hospitals, health systems, colleges, universities, pharmaceutical and biotech companies, health care insurers, medical de vice and supply companies, and other educational institutions. The company was founded in 1979 and is headquartered in Washington, District of Columbia.
Advisors' Opinion: - [By Ben Levisohn]
Krishna and Krauklis note that Buffalo Wild Wings, Nextera Energy (NEP), Rexnord Corp (RXN), and The Advisory Board (ABCO) should benefit from recent acquisitions that should boost revenue growth, while�Buffalo Wild Wings and Cavium (CAVM) should see improvements thanks to the adoption of new technology that will help boost margins. Terex, The Advisory Board, and�Rexnord should get a boost from cost cutting, Krishna and Krauklis say.
Top 10 Gas Utility Companies To Own For 2015: Pain Therapeutics Inc (PTIE)
Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.
REMOXY
REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.
Metastatic Melanoma
The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.
Hemophilia
The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).
Other product candidates
The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.
The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.
Advisors' Opinion: - [By Sean Williams]
However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.
- [By Jessica Alling]
Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.
Top 10 Gas Utility Companies To Own For 2015: EXACT Sciences Corporation(EXAS)
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect each of the four stages of colorectal cancer, as well as pre-cancerous lesions. Its test includes proprietary and patented methods, which isolate and analyze the trace amounts of human DNA that are shed into stool every day from the exfoliation of cells that line the colon. The company?s Cologuard test is also used to detect blood in stool, utilizing an antibody-based fecal immunochemical test. It has a strategic alliance agreement with LabCorp under which it licenses its patents and patent applications relating to the stool-based colorectal cancer screening technology to LabCorp; a collaboration, license, and purchase agreement with Genzyme Corporation to d eliver intellectual property improvements through licenses; and a license agreement with MAYO Foundation for medical education and research. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Advisors' Opinion: - [By Sean Williams]
What: Shares of EXACT Sciences (NASDAQ: EXAS ) , a molecular diagnostics company focused on cancer and pre-cancer colorectal screening tests, nosedived as much as 30% following the release of top-line data from the company's Deep-C clinical trial for Cologuard.
- [By Daniel Lauchheimer]
In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.
- [By Keith Speights]
Year-to-date gains of 25% don't really tell the full story for molecular diagnostics company Exact Sciences (NASDAQ: EXAS ) . There have been plenty of big ups and downs to get to those 25% gains. Since late April, the stock is actually up almost 70%.
Top 10 Gas Utility Companies To Own For 2015: C&F Financial Corporation(CFFI)
C&F Financial Corporation operates as the holding company for Citizens and Farmers Bank that provides various banking and related financial services to individuals and businesses. It operates through three segments: Retail Banking, Mortgage Banking, and Consumer Finance. The Retail Banking segment offers various types of checking and savings deposit accounts; business, real estate, development, mortgage, home equity, and installment loans; and ATMs, Internet banking, and credit cards, as well as travelers? checks, safe deposit box rentals, collection, notary public, wire service, and other customary bank services. This segment provides retail banking services at its main office in West Point, Virginia; and 17 branches in Chester, Hampton, Mechanicsville, Midlothian, Newport News, Norge, Providence Forge, Quinton, Saluda, Sandston, Varina, West Point, Yorktown, Williamsburg, and Richmond, Virginia. The Mortgage Banking segment originates conventional mortgage loans, mortga ge loans insured by the Federal Housing Administration, mortgage loans partially guaranteed by the Veterans Administration, and home equity loans. This segment provides mortgage loan origination services through 15 locations in Virginia, 4 in Maryland, and 2 in North Carolina, as well as 1 each in Wilmington, Delaware; Moorestown, New Jersey; and York, Pennsylvania. The Consumer Finance segment provides automobile loans in Virginia and in portions of Alabama, Indiana, Kentucky, Maryland, North Carolina, Ohio, Tennessee, Georgia, and West Virginia through offices in Richmond and Hampton, Virginia; Nashville, Tennessee; and Towson, Maryland. The company also offers brokerage services, and insurance and title insurance services. C&F Financial Corporation was founded in 1927 and is based in West Point, Virginia.
Advisors' Opinion: - [By Doug Hughes]
An example of that would be C&F Financial (CFFI) in Westport, Virginia. The CEO, Larry Dillon, has been there for 35 years, plus, the bank is trading at a p/e of 6 or 7, if you can believe it. It's only $2 over book value.
Top 10 Gas Utility Companies To Own For 2015: Credit Suisse Group AG (CSGN)
Credit Suisse Group AG is a Switzerland-based holding company engaged in private banking, investment banking and asset management areas. It operates through four divisions: Private Banking, which consists of the Wealth Management Clients and Corporate & Institutional Clients business; Investment Banking, provides a range of financial products and services, with a focus on client-driven, flow-based and capital-efficient businesses; Asset Management, offers a range of asset class products, including alternative investments, and multi-asset class solutions, including equities and fixed income products, and Shared Services, which provides centralized corporate services and business support for the Company's divisions.
Advisors' Opinion: - [By Ruth David]
Credit Suisse Group AG (CSGN) and Numis Securities Ltd. managed the sale, along with Canaccord Genuity Ltd. Rothschild acted as financial adviser.
- [By Marie Mawad]
Orange was advised by Credit Suisse Group AG (CSGN) and Messier, Maris & Associes. Altice was advised by Lazard Ltd. Goldman Sachs Group Inc lead the financing on the deal, working with Morgan Stanley, Deutsche Bank AG, Barclays Plc and Credit Agricole SA.